• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Iranian journal of medical hypotheses and ideas. >Maximum inhibition of breast cancer/stem cell growth by concomitant blockage of key receptors
【24h】

Maximum inhibition of breast cancer/stem cell growth by concomitant blockage of key receptors

机译：通过同时阻断关键受体最大程度地抑制乳腺癌/干细胞的生长

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The blockage of cancer cell growth and division is the prime objective in clinical cancer therapy both at early stages and for inhibition of minimal residual disease and relapse. The failure of conventional therapies in treating breast cancer (BC) has prompted dissection of signalling pathways involved in BC cell growth and characterisation of cellular receptors. Specific sets of membrane-bound receptors promote disarrayed self-renewal of BC stem cells and deregulated BC cell proliferation. Individual blockage of each receptor promotes only incomplete inhibition of BC cell growth and partial regression of metastasis. Such monotherapies are based on either chemotherapy or monoclonal antibodies. However, they do not provide long-lasting benefits and are further compromised by increasing resistance the cancer cells acquire against therapeutic agents, by their evasion of receptor blockage and by adoption of alternative growth routes that are induced by cross-talks between key receptors. On the other hand, dual targeting approaches, including receptor blockage combined with chemotherapy, produce prolonged overall survival but, nevertheless, complicate treatment by inducing side effects. Based on the complex nature of BC, combined targeted strategies that potentially confer maximum coverage for treatment cannot be effective without overcoming drug resistance initiated and further induced by inter-receptor communications. This implies that a comprehensive strategy based on concomitant inhibition of key receptors could provide an ultimate solution for effective treatment of aggressive types of BC. Such a strategy would likely be capable of targeting breast tumour cells and BC stem cells alike eventually forcing the cancer to regress.
机译：癌细胞生长和分裂的阻断是早期临床癌症治疗的主要目的，并且是抑制最小残留疾病和复发的主要目标。传统疗法在治疗乳腺癌（BC）中的失败促使解剖涉及BC细胞生长和细胞受体表征的信号通路。特定的膜结合受体组促进BC干细胞混乱的自我更新和BC细胞增殖失控。每个受体的单独阻滞仅促进对BC细胞生长的不完全抑制和转移的部分消退。这样的单一疗法基于化学疗法或单克隆抗体。然而，它们不能提供长期的益处，并且由于癌细胞获得的对治疗剂的抗性增加，其逃避受体阻滞作用以及通过采用由关键受体之间的串扰诱导的替代生长途径而进一步受到损害。另一方面，双重靶向方法，包括受体阻滞与化学疗法相结合，可延长总体生存期，但由于引起副作用而使治疗复杂化。基于BC的复杂性，如果不克服由受体间通讯引发和进一步诱导的耐药性，则可能具有最大治疗覆盖率的联合靶向策略是无效的。这意味着基于同时抑制关键受体的综合策略可以为有效治疗侵袭性类型的BC提供最终解决方案。这样的策略很可能能够靶向乳腺肿瘤细胞和BC干细胞，最终迫使癌症消退。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号